• Vaccine Name: MA-ExoN vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Live, attenuated vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: MA-ExoN (Graham et al., 2012)
• Immunization Route: intranasal immunization
• Description: Live-attenuated RNA virus vaccine with engineered inactivation of SARS-CoV ExoN activity (MA-ExoN) (Graham et al., 2012)

Mouse Response

• Host Strain: Balb/c(Graham et al., 2012)
• Host age: 10 weeks (Graham et al., 2012)
• Host gender: Female (Graham et al., 2012)
• Vaccination Protocol: intranasally with varying doses (10^2–10^4 PFU, depending on the experiment) of SARS-CoV MA-ExoN (Graham et al., 2012)
• Immune Response: generated high levels of neutralizing antibodies (Graham et al., 2012)
• Challenge Protocol: intranasally injected 1e2.5 vaccination PFU of vaccine of SARS-CoV MA-ExoN then given SARS-CoV once recovered (Graham et al., 2012)
• Efficacy: complete protection (Graham et al., 2012)